Comparative Pharmacology
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus QUADRAMET.
CHLORMERODRIN HG 197 vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical